Information Provided By: 
Fly News Breaks for October 13, 2015
MDXG
Oct 13, 2015 | 07:30 EDT
Brean Capital noted MiMedx preannounced slightly better than expected Q3 revenues ahead of the company's analyst meeting today. The firm feels there could be some investor disappointment as the company narrowed its top end guidance due to distributor adjustments, but believes MiMedx should be able to continue to grow above 20% over at least the next three years. Brean Capital reiterated its Buy rating and $16 price target on MiMedx shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
